Source: Virtual Congress 2020 – Molecular alterations and immunology in lung cancer
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
S. Yang (Iksan, Republic of Korea), M. Kim (Iksan, Republic of Korea), S. Kim (Iksan, Republic of Korea), M. Kim (Iksan, Republic of Korea). Reduction of drug resistance through calcium control in epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) resistant lung cancer cells. 1648

Member's Comments

No comment yet.

Related content which might interest you: EGFR-TKI and lung adenocarcinoma with CNS relapse: interest of molecular follow-up Source: Eur Respir J 2009; 33: 436-440 Year: 2009 Epidermal growth factor receptor (EGFR) gene mutation testing prior to tyrosine kinase inhibitors (TKI) treatment – prospective data from the Czech TULUNG registry Source: Virtual Congress 2020 – Real-world data and registries of thoracic oncology Year: 2020 Targeted therapy in nonsmall cell lung cancer Source: Eur Respir Mon; 2009: 44: 284–298 Year: 2009 Use of multitarget tyrosine kinase inhibitors to attenuate platelet-derived growth factor signalling in lung disease Source: Eur Respir Rev, 26 (146) 170061; 10.1183/16000617.0061-2017 Year: 2017 Safety and efficacy of an inhaled epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (BIBW 2948) in COPD Source: Annual Congress 2009 - New drugs for airways disease Year: 2009 Targeting STAT3 pathway signalling in EGFR TKI resistant NSCLC Source: Virtual Congress 2020 – Chronic lung diseases: novel methods, diagnostics and biomarkers Year: 2020 Synergistic anti-tumor effects of vandetanib, an inhibitor of VEGFR and EGFR tyrosine kinase inhibitor, combined with cytotoxic agents in lung cancer cell lines Source: Annual Congress 2010 - Treatment of lung cancer Year: 2010 Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma Source: Eur Respir J 2012; 39: 366-372 Year: 2012 Blocking beta adrenergic signaling may be a target for overcoming EGFR TKI resistance. Source: International Congress 2018 – Lung cancer: from the bench to the bedside Year: 2018 Detection of epidermal growth factor receptor mutation in plasma as predictor of gefitinib response in non small cell lung cancer Source: Annual Congress 2008 - Therapy in thoracic oncology Year: 2008 EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR wild-type pre-treated advanced nonsmall cell lung cancer in daily practice Source: Eur Respir J, 50 (2) 1700514; 10.1183/13993003.00514-2017 Year: 2017 Frequent EGFR mutations in nonsmall cell lung cancer presenting with miliary intrapulmonary carcinomatosis Source: Eur Respir J 2013; 41: 417-424 Year: 2013 Bradykinin phosphorylates ERK1/2 through epidermal growth factor receptor transactivation in human lung fibroblasts Source: Eur Respir J 2005; 26: Suppl. 49, 341s Year: 2005 Efficacy of Afatinib, Erlotinib, and Gefitinib on epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC) patients with brain metastasis: a network meta-analysis Source: International Congress 2018 – Lung cancer: modern therapies and beyond Year: 2018 Effect of PDGF receptor tyrosine kinase inhibitor AG1296 on bleomycin-induced lung fibrosis in mice Source: Annual Congress 2004 - Pulmonary fibrosis - new insights Year: 2004 SiRNA mediated growth factor receptors inhibition in A549 cell model of lung cancer gene therapy: insulin-like growth factor-I receptor (IGF-R1) blockade produces changes that potentially induce anti-tumor immunity Source: Annual Congress 2008 - Biology in thoracic tumours Year: 2008 Clinical profile of newly diagnosed patients of non small cell carcinima with epidermal growth factor receptor positivity on oral tyrosine kinase inhibitor therapy Source: Annual Congress 2013 –Systemic therapy of lung cancer and quality of life Year: 2013 The predictive value of circulating tumor DNA dynamics in plasma of EGFR-mutation-positive NSCLC patients on first line tyrosine kinase inhibitors Source: Virtual Congress 2021 – New clinical and biological developments in lung cancer Year: 2021 Lung adenocarcinoma patients of young age have lower EGFR mutation rate and poorer efficacy of EGFR tyrosine kinase inhibitors Source: ERJ Open Res, 3 (3) 00092-2016; 10.1183/23120541.00092-2016 Year: 2017